Inquiry Basket
Polymer-Based Drug Delivery Platform Services
Drug Delivery Platforms
BOC Sciences provides polymer-based drug delivery platform development services for controlled release, sustained delivery, payload protection, solubility enhancement, localized administration, and route-adaptable formulation development.
Integrated Platform Development Support
Our portfolio spans nanoparticles, micelles, microspheres, hydrogels, microneedles, implants, nanogels, vesicles, microcapsules, patches, inserts, and wafers.
- Platform selection based on payload, route, and release goals
- Polymer design, carrier preparation, and prototype development
- Drug loading, characterization, and release evaluation
- Optimization guidance for polymer platform development
Why Platform Selection Matters in Drug Delivery Development
Drug delivery platform selection influences drug loading, release kinetics, stability, administration route compatibility, manufacturability, scalability, and analytical strategy. Hydrophobic small molecules often require solubilization or encapsulation approaches, while peptides, proteins, antibodies, and nucleic acids typically require protection against degradation and carefully controlled release environments.
Polymer delivery platforms vary widely in architecture and release mechanisms. Nanoparticles, micelles, nanogels, microspheres, hydrogels, implants, inserts, wafers, patches, and microneedles each provide unique combinations of material behavior and delivery performance. BOC Sciences helps clients identify platform strategies that align with drug properties, release objectives, and formulation development goals.
Release Mechanism Selection
The selected platform determines whether drug release is governed by diffusion, polymer degradation, swelling, erosion, micelle dissociation, membrane permeability, matrix structure, or device geometry. Early platform selection helps reduce formulation risk and guides polymer composition, molecular weight, architecture, and processing strategy.
Payload-Driven Platform Design
Small molecules, peptides, proteins, antibodies, nucleic acids, and vaccines differ in solubility, charge, molecular size, stability, dose requirement, and sensitivity to processing. Platform design must account for these differences to achieve appropriate loading, protection, and release performance.
Polymer Engineering for Delivery Performance
Polymer composition, degradability, crosslinking, hydrophilicity, surface properties, porosity, particle size, and mechanical characteristics all influence platform behavior. Rational polymer engineering helps connect material chemistry with formulation goals and delivery performance.
Common Challenges in Drug Delivery Platform Development
Drug delivery platform development requires balancing drug loading, payload stability, release control, carrier architecture, material compatibility, processing conditions, and characterization requirements. Platform-specific challenges vary substantially depending on whether the system is nano-scale, micro-scale, hydrogel-based, implantable, transdermal, localized, or device-associated.
Platform-Drug Compatibility
Drug solubility, polarity, charge, crystallinity, and stability can affect carrier formation, loading, release behavior, and storage performance.
Drug Loading and Encapsulation Efficiency
Different platforms require different loading strategies, including encapsulation, self-assembly, matrix incorporation, adsorption, coating, or reservoir filling.
Controlled and Sustained Release Design
Release profiles depend on polymer chemistry, matrix structure, degradation, swelling, diffusion pathways, particle size, membrane permeability, and geometry.
Payload Stability During Processing
Proteins, peptides, nucleic acids, and sensitive small molecules may require mild processing conditions and stabilizing polymer environments.
Particle, Matrix, or Device Morphology Control
Size, porosity, shape, film thickness, needle geometry, network density, and capsule shell properties influence delivery performance.
Platform Characterization and Optimization
Reliable development requires platform-specific characterization to interpret performance and guide rational polymer or process optimization.
Our Polymer-Based Drug Delivery Platform Portfolio
BOC Sciences provides a comprehensive portfolio of polymer-based drug delivery platforms spanning nano-scale carriers, controlled-release particles, hydrogel systems, implantable matrices, transdermal systems, and localized delivery devices. Each platform can be customized according to drug properties, delivery route, release duration, and formulation objectives.
Polymer Nanoparticle Platform
Polymeric nanoparticles support nanoscale carrier development, payload protection, surface modification, controlled release, and route-adaptable delivery for small molecules, peptides, proteins, and nucleic acids.
- Particle size, PDI, zeta potential, and morphology control
- PLGA, PLA, PCL, PEGylated polymers, and functional copolymers
- Drug loading, encapsulation, and release evaluation
Polymer Micelle Platform
Polymer micelles are useful for hydrophobic drug solubilization and self-assembled nanocarrier development using amphiphilic block copolymers.
- CMC, micelle stability, and loading capacity evaluation
- PEG-PLA, PEG-PLGA, PEG-PCL, and related copolymers
- Release behavior and route-adaptable carrier design
Polymer Microsphere Platform
Polymer microspheres support long-acting release, depot formulation development, injectable controlled-release systems, and biodegradable particle-based delivery.
- PLGA and biodegradable polymer microspheres
- Particle size, morphology, and burst release control
- In vitro release and degradation evaluation
Polymer Hydrogel Platform
Polymer hydrogels provide hydrated matrices for local retention, diffusion-controlled release, in situ gelation, swelling-controlled delivery, and soft material environments.
- PEG, PVA, alginate, hyaluronic acid, and chitosan systems
- Gelation, swelling, crosslinking, and mechanical tuning
- Hydrogel matrices for sensitive payloads
Polymer Microneedle Platform
Polymer microneedles support transdermal, intradermal, and minimally invasive delivery through dissolving, biodegradable, or hydrogel-forming needle arrays.
- Needle geometry and mechanical strength assessment
- Drug loading and matrix distribution optimization
- Patch-based microneedle array development
Polymer Implant Platform
Polymer implants support long-acting localized or systemic release through biodegradable matrices, reservoirs, hydrogel implants, and in situ forming systems.
- Implant geometry, degradation, and mechanical behavior
- PLGA, PLA, PCL, PEG hydrogel, and functional matrices
- Burst release and incomplete release optimization
Polymer Nanogel Platform
Polymer nanogels provide crosslinked nanoscale networks for responsive release, hydrophilic payload loading, and biologic-friendly carrier environments.
- pH-, redox-, temperature-, or enzyme-responsive networks
- Swelling and network architecture tuning
- Nanogel characterization and release evaluation
Polymer Vesicle Platform
Polymer vesicles, including polymersome-like carriers, provide aqueous core and hydrophobic membrane domains for dual loading and membrane-controlled delivery.
- Amphiphilic block copolymer vesicles
- Membrane thickness, stability, and permeability tuning
- Size, morphology, and release characterization
Polymer Microcapsule Platform
Polymer microcapsules provide core-shell architectures for reservoir-style release, payload protection, and membrane-controlled diffusion.
- Shell thickness, permeability, and stability control
- Core-shell encapsulation for small molecules or biologics
- Coacervation, interfacial polymerization, or layer-by-layer approaches
Polymer Patch Platform
Polymer patches support transdermal and local delivery using drug-in-adhesive systems, matrix patches, controlled-release films, and skin-contact materials.
- Adhesive, film-forming, and matrix polymer design
- Drug migration, crystallization, and release rate control
- Adhesion, flexibility, and wear performance support
Polymer Insert Platform
Polymer inserts can support ocular, mucosal, local, or cavity-associated delivery through thin films, strips, matrices, or drug-eluting insert systems.
- Biodegradable or non-biodegradable insert matrices
- Film thickness, hydration, swelling, and handling properties
- Local retention and controlled release evaluation
Polymer Wafer Platform
Polymer wafers support localized delivery, tissue-interface release, biodegradable matrix design, and sustained exposure from solid wafer-like systems.
- Drug-loaded polymer wafer design
- Wafer thickness, porosity, mechanical strength, and degradation
- Localized sustained release optimization
Need Help Selecting the Right Polymer Platform?
Share your drug modality, delivery route, release target, and formulation challenge. We can help identify suitable platform options and development steps.
Polymer Platforms by Delivery Scale and Structure
Polymer drug delivery platforms can be categorized by carrier scale and dosage form architecture, including nano-scale carriers, micro-scale carriers, hydrogel networks, skin-contact or minimally invasive systems, implantable systems, and localized device-associated platforms. This classification helps clients understand that platform selection is not based only on platform name, but on drug properties, administration route, release objectives, and material behavior.
Nano-Scale Carrier Platforms
Nano-scale platforms are often used when the project requires improved dispersion, solubility enhancement, payload protection, surface modification, nanoscale transport, or functional carrier engineering.
- Solubility enhancement for poorly soluble payloads
- Protection of sensitive or unstable molecules
- Surface modification and functional carrier design
- Nanoscale delivery and controlled release exploration
Micro-Scale Controlled Release Platforms
Micro-scale platforms are commonly explored when the project requires depot-like release, longer release duration, particle-based encapsulation, reservoir-style control, or reduced dosing frequency.
- Depot release and sustained exposure support
- Long-acting injectable formulation development
- Encapsulation and protection of active payloads
- Particle-based controlled release optimization
Network and Matrix Platforms
Network and matrix platforms are suitable for projects requiring hydrated environments, local retention, swelling-controlled release, implantable release, soft or solid matrix delivery, and long-term exposure.
- Local retention and site-specific exposure
- Swelling-controlled or diffusion-controlled release
- Soft or solid matrix-based delivery formats
- Long-term release and sustained payload exposure
Skin-Contact and Minimally Invasive Platforms
Skin-contact and minimally invasive platforms can support transdermal delivery, intradermal delivery, controlled skin exposure, local retention, and delivery exploration for molecules that require barrier-bypassing strategies.
- Transdermal or intradermal delivery development
- Controlled exposure through skin-contact systems
- Barrier-bypassing delivery for complex payloads
- Skin retention and localized release support
Localized Device-Associated Platforms
Localized device-associated platforms are suitable for projects requiring local tissue release, post-placement controlled exposure, site-specific retention, or drug release from implantable or insert-like formats.
- Ocular, mucosal, or local tissue delivery
- Post-placement controlled release support
- Device-associated or site-specific exposure
- Localized retention with reduced systemic distribution
Implantable and Long-Acting Platforms
Implantable and long-acting platforms are designed for projects that require prolonged drug exposure, reduced dosing frequency, localized retention, or controlled release over weeks to months.
- Long-term controlled and sustained release
- Reduced dosing frequency and improved treatment convenience
- Localized retention with prolonged drug exposure
- Customizable degradation and release kinetics
Platform Selection Based on Therapeutic Modality
Different therapeutic modalities impose different requirements on carrier architecture, release mechanism, payload protection, and administration strategy. Understanding these relationships helps guide platform selection and formulation planning before committing to a single polymer system.
| Therapeutic Modality | Key Delivery Challenges | Suitable Polymer Platforms |
|---|---|---|
| Poorly Soluble Small Molecules | Solubility, dispersion, release control | Micelles, nanoparticles, patches, implants |
| Hydrophilic Small Molecules | Diffusion control, retention | Hydrogels, microcapsules, inserts |
| Peptides | Stability, sustained release | Hydrogels, microspheres, microneedles, implants |
| Proteins | Aggregation, denaturation | Hydrogels, nanogels, nanoparticles |
| Antibodies | Large size, prolonged exposure | Hydrogels, implants, reservoir systems |
| Nucleic Acids | Degradation, carrier protection | Nanoparticles, nanogels, vesicles |
| Vaccines / Antigens | Stability and controlled exposure | Microneedles, nanoparticles, microparticles |
| Localized Therapies | Retention and local release | Inserts, wafers, implants |
| Long-Acting Therapies | Sustained release | Microspheres, implants, wafers |
How We Support Drug Delivery Platform Development
BOC Sciences supports platform development from early-stage platform screening through polymer design, carrier fabrication, characterization, release evaluation, and optimization. Support can be tailored to individual platforms or comparative development programs based on drug modality, route requirements, release targets, and project stage.
Platform Feasibility Assessment
We review drug modality, physicochemical properties, route requirements, dosage form goals, release duration, and key formulation risks to identify suitable polymer platforms.
- Drug modality and property review
- Route and dosage form assessment
- Target release duration analysis
- Initial platform suitability screening
Polymer Selection and Functional Design
Polymer candidates are selected according to degradability, amphiphilicity, crosslinking, mechanical behavior, functional groups, molecular weight, and carrier formation needs.
- Biodegradable polymer screening
- Amphiphilic copolymer design
- Hydrogel and network selection
- Functional group and surface chemistry planning
Carrier or Matrix Prototype Development
Prototype platforms are prepared using appropriate methods for nanoparticles, micelles, vesicles, nanogels, microspheres, hydrogels, implants, patches, inserts, and wafers.
- Nano-scale and micro-scale carrier preparation
- Matrix, hydrogel, patch, implant, and wafer fabrication
- Prototype comparison and processing method selection
- Platform-specific preparation optimization
Drug Loading and Stability Optimization
Loading strategies are optimized to improve encapsulation, compatibility, uniformity, stability, and release behavior while reducing leakage, burst release, or aggregation risks.
- Encapsulation and loading strategy
- Drug-polymer compatibility evaluation
- Loading uniformity and distribution analysis
- Payload stability and leakage control
Characterization and Performance Evaluation
Platform-specific characterization helps interpret formulation behavior, identify risks, and guide rational improvement of carrier architecture or polymer composition.
- Particle size, morphology, PDI, and zeta potential
- Matrix structure, swelling, degradation, and mechanics
- Surface properties and coating behavior
- In vitro release profiling
Platform Optimization and Development Guidance
We provide practical recommendations for polymer adjustment, carrier redesign, processing changes, loading improvement, release tuning, and next-stage platform development.
- Polymer composition adjustment
- Carrier architecture redesign
- Release profile refinement
- Next-stage development recommendations
Drug Delivery Platform Development Workflow
Our workflow is designed to guide projects from delivery challenges to platform selection, prototype preparation, characterization, release testing, and optimization. This structured process helps identify the most suitable polymer platform while reducing unnecessary development iterations.
Drug and Delivery Goal Assessment
We begin by reviewing the therapeutic modality, molecular weight, solubility, stability, charge characteristics, dosage requirements, target administration route, delivery site, and intended release duration. This assessment establishes the fundamental performance requirements for platform selection and helps identify potential formulation risks at an early stage.
Platform Shortlisting
Candidate delivery platforms are evaluated according to drug properties, delivery objectives, and formulation constraints. We compare carrier architectures, release mechanisms, administration route compatibility, and development feasibility to identify the most appropriate platform categories for further investigation and prototype development.
Polymer and Material Selection
Suitable polymers and supporting materials are selected based on degradability, hydrophilicity, molecular weight, functional groups, mechanical requirements, carrier-forming capability, and drug compatibility. Material selection is guided by the desired release profile, platform architecture, and overall development objectives.
Prototype Platform Preparation
Initial prototypes are prepared using platform-specific fabrication methods such as nanoprecipitation, self-assembly, emulsification, spray drying, gelation, crosslinking, film casting, coating, micromolding, or matrix fabrication. Prototype preparation allows preliminary evaluation of carrier formation, drug incorporation, and structural integrity.
Drug Loading and Formulation Screening
Drug loading approaches are optimized to achieve suitable encapsulation efficiency, payload distribution, formulation stability, and release performance. Multiple formulation variables may be screened to identify conditions that support consistent carrier quality and reduce the risk of burst release, leakage, or instability.
Characterization and Release Testing
Prototype systems undergo characterization using platform-relevant analytical methods. Depending on the platform type, evaluations may include particle size, morphology, surface properties, swelling behavior, degradation profile, mechanical properties, drug loading, encapsulation efficiency, and in vitro release performance.
Data Interpretation and Platform Refinement
Experimental results are analyzed to identify relationships between polymer composition, carrier architecture, processing conditions, and release behavior. This stage helps determine the dominant release mechanisms, evaluate formulation limitations, and prioritize modifications that may improve overall platform performance.
Optimization Recommendations
Based on the collected development data, we provide recommendations for polymer selection, formulation refinement, carrier redesign, release profile adjustment, and additional characterization studies. These recommendations help define practical next steps for continued platform development and project advancement.
Deliverables for Drug Delivery Platform Development
Deliverables are tailored to project scope and may include platform selection rationale, polymer recommendations, prototype systems, characterization data, release profiles, and development guidance. These outputs help clients compare platform options and decide which direction is most suitable for further development.
Platform Selection Report
Summarizes drug properties, delivery objectives, platform options, key risks, and recommended development direction.
Polymer and Material Recommendation Package
Provides suggested polymer classes, molecular weight considerations, architecture guidance, and platform-specific material rationale.
Prototype Platform Formulations
May include nanoparticles, micelles, microspheres, hydrogels, microneedles, implants, nanogels, vesicles, patches, inserts, or wafers.
Drug Loading and Stability Data
Includes loading efficiency, encapsulation behavior, compatibility observations, leakage risks, and stability-related findings.
Characterization Data Package
Provides size, morphology, surface behavior, matrix structure, swelling, degradation, mechanical, or coating-related results.
Release Evaluation Report
Includes release profiles, burst release observations, sustained-release comparison, and interpretation of platform behavior.
Why Choose BOC Sciences for Drug Delivery Platform Development?
BOC Sciences combines polymer chemistry expertise, carrier engineering capabilities, characterization resources, and controlled-release development experience to support customized drug delivery platform projects across a broad range of polymer technologies.
Broad Polymer Platform Coverage
We support nano-scale carriers, micro-scale particles, hydrogels, patches, microneedles, implants, inserts, wafers, vesicles, nanogels, and microcapsules.
Polymer Chemistry and Material Design Expertise
Polymer composition, molecular weight, architecture, functional groups, degradability, crosslinking, and surface properties can be adjusted to platform needs.
Custom Platform Engineering
Each platform can be engineered according to size, morphology, matrix structure, mechanical behavior, swelling, permeability, degradation, and route-specific requirements.
Integrated Characterization Support
Characterization data help compare prototypes, evaluate risks, interpret release mechanisms, and guide rational optimization.
Flexible Research-Stage Collaboration
Projects can be structured as feasibility studies, platform comparison, prototype development, polymer modification, release evaluation, or optimization programs.
Conversion-Focused Technical Communication
We help translate delivery challenges into practical platform options, clear development steps, and defined deliverables for project scoping.
Frequently Asked Questions
These questions address common considerations for polymer drug delivery platform selection, comparison, customization, and project preparation.
What is a drug delivery platform?
A drug delivery platform is a material, carrier, matrix, or device system designed to load, protect, release, or localize a therapeutic payload. Polymer-based platforms may include nanoparticles, micelles, hydrogels, microspheres, microcapsules, patches, implants, inserts, wafers, vesicles, nanogels, and microneedles.
How do I choose the right polymer drug delivery platform?
Platform selection depends on drug modality, solubility, stability, molecular size, dose, route of administration, release duration, and dosage form target. The best platform is usually selected by matching payload limitations with carrier architecture, polymer properties, release mechanism, and characterization requirements.
Which platforms are suitable for poorly soluble drugs?
Poorly soluble drugs are often evaluated with polymer micelles, nanoparticles, hydrophobic matrices, patches, or implant systems. Micelles can improve apparent solubility, while nanoparticles and matrices can support dispersion, encapsulation, and release control. Final selection depends on dose, route, and stability.
Which platforms are suitable for peptides and proteins?
Peptides and proteins may be explored using hydrogels, nanogels, mild-preparation nanoparticles, microspheres, microneedles, inserts, or implants. These payloads often require careful attention to aggregation, denaturation, enzymatic exposure, and release environment, so platform design should prioritize stability-preserving conditions.
What is the difference between nanoparticles, microspheres, and microcapsules?
Nanoparticles are nanoscale carriers used for protection, surface modification, and controlled delivery. Microspheres are typically micron-scale matrix particles for sustained or depot release. Microcapsules usually have core-shell structures where shell permeability and thickness help regulate reservoir-style release.
Can one drug use more than one delivery platform?
Yes. Early-stage projects often compare multiple platforms, such as nanoparticles versus micelles, hydrogels versus nanogels, or microspheres versus implants. Comparative screening can help determine which platform better supports drug loading, stability, release control, administration route, and development feasibility.
Do you support custom polymer platform development?
Yes. BOC Sciences supports custom polymer platform development, including polymer selection, carrier preparation, surface modification, drug loading, matrix design, characterization, release evaluation, and optimization. Services can be configured for feasibility assessment, platform comparison, prototype development, or focused performance improvement.
What information is needed to start a platform development project?
Useful starting information includes drug type, molecular weight, structure, solubility, stability, dose, target route, desired release duration, preferred platform, available sample amount, analytical methods, and known formulation challenges. If some data are unavailable, the project can begin with feasibility assessment.
Submit Your Drug Delivery Project Inquiry
Please share your drug modality, molecular weight, solubility and stability information, intended administration route, target release duration, preferred platform, and current formulation challenge. Our team can help propose a suitable polymer delivery platform strategy.
- Polymer drug delivery platform selection
- Nano-scale, micro-scale, hydrogel, implant, patch, insert, and wafer systems
- Polymer selection, carrier development, loading, and characterization
- Release evaluation and platform optimization guidance
